116 related articles for article (PubMed ID: 23920036)
1. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
Lund BT; Kelland EE; Hayardeny L; Barilan O; Gilmore W; Weiner LP
J Neuroimmunol; 2013 Oct; 263(1-2):108-15. PubMed ID: 23920036
[TBL] [Abstract][Full Text] [Related]
2. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
3. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.
Toubi E; Nussbaum S; Staun-Ram E; Snir A; Melamed D; Hayardeny L; Miller A
J Neuroimmunol; 2012 Oct; 251(1-2):45-54. PubMed ID: 22846497
[TBL] [Abstract][Full Text] [Related]
4. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
[TBL] [Abstract][Full Text] [Related]
5. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
[TBL] [Abstract][Full Text] [Related]
6. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Filippi M; Rocca MA; Pagani E; De Stefano N; Jeffery D; Kappos L; Montalban X; Boyko AN; Comi G;
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):851-8. PubMed ID: 24029546
[TBL] [Abstract][Full Text] [Related]
8. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
Stasiolek M; Linker RA; Hayardeny L; Bar Ilan O; Gold R
Immun Inflamm Dis; 2015 Jun; 3(2):45-55. PubMed ID: 26029365
[TBL] [Abstract][Full Text] [Related]
9. Oral laquinimod treatment in multiple sclerosis.
Fernández O
Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
[TBL] [Abstract][Full Text] [Related]
10. Insight into the mechanism of laquinimod action.
Brück W; Wegner C
J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
[TBL] [Abstract][Full Text] [Related]
11. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Thöne J; Gold R
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281
[TBL] [Abstract][Full Text] [Related]
12. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.
Mishra MK; Wang J; Silva C; Mack M; Yong VW
Am J Pathol; 2012 Aug; 181(2):642-51. PubMed ID: 22749771
[TBL] [Abstract][Full Text] [Related]
14. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Zilkha-Falb R; Gurevich M; Hayardeny L; Achiron A
J Neuroimmunol; 2015 Jun; 283():11-6. PubMed ID: 26004150
[TBL] [Abstract][Full Text] [Related]
15. Oral laquinimod therapy in relapsing multiple sclerosis.
Preiningerova J
Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
[TBL] [Abstract][Full Text] [Related]
16. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Tselis A
Curr Opin Investig Drugs; 2010 May; 11(5):577-85. PubMed ID: 20419604
[TBL] [Abstract][Full Text] [Related]
17. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients.
Skarica M; Eckstein C; Whartenby KA; Calabresi PA
J Neuroimmunol; 2011 Jun; 235(1-2):70-6. PubMed ID: 21550672
[TBL] [Abstract][Full Text] [Related]
18. Laquinimod in the treatment of multiple sclerosis: a review of the data so far.
Thöne J; Linker RA
Drug Des Devel Ther; 2016; 10():1111-8. PubMed ID: 27042003
[TBL] [Abstract][Full Text] [Related]
19. Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS.
Engel S; Jolivel V; Kraus SH; Zayoud M; Rosenfeld K; Tumani H; Furlan R; Kurschus FC; Waisman A; Luessi F
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33203651
[TBL] [Abstract][Full Text] [Related]
20. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Constantinescu SE; Constantinescu CS
Expert Rev Clin Pharmacol; 2016; 9(1):49-57. PubMed ID: 26536299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
